<DOC>
	<DOCNO>NCT02096965</DOCNO>
	<brief_summary>In study investigator propose use daily dose 45 mg ( 30 mg 8 AM 15 mg 4 PM ) . This relatively small well-tolerated dose likely persistently increase urine volume reduce urine supersaturation well tolerated patient kidney stone disease normal renal function ( see ) . The twice-daily ( 8 AM 4 PM ) regimen design produce maximal AVP inhibition wake gradual fall-off effect night . To end , high dose use morning , low dose afternoon .</brief_summary>
	<brief_title>Use Tolvaptan Reduce Urinary Supersaturation : Pilot Proof Principle Study</brief_title>
	<detailed_description />
	<mesh_term>Nephrolithiasis</mesh_term>
	<mesh_term>Kidney Calculi</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>History calcium oxalate calcium phosphate stone . Good renal function History hypoor hypernatremia . History hypotension orthostatic dizziness . Clinical history congestive heart failure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Calcium oxalate</keyword>
	<keyword>Calcium phosphate</keyword>
	<keyword>Kidney stone</keyword>
</DOC>